Gnanapavan's research team compared the differences in CSF NCAM levels in control populations with benign intracranial hypertension, multiple sclerosis, cases of AD, motor neuron disease, and meningitis and found that its levels in multiple sclerosis, AD, and meningitis are reduced [26]. Here, NCAM1 is linked to intracranial hypertension.